Synlogic, Inc. (NASDAQ:SYBX) Sees Large Growth in Short Interest

Synlogic, Inc. (NASDAQ:SYBX) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 88,300 shares, an increase of 42.9% from the November 30th total of 61,800 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 30,200 shares, the short-interest ratio is currently 2.9 days.

Synlogic Price Performance

Shares of NASDAQ SYBX traded down $0.05 during midday trading on Friday, reaching $1.36. 72,705 shares of the stock traded hands, compared to its average volume of 51,174. The company’s 50 day moving average is $1.42 and its 200 day moving average is $1.48. Synlogic has a one year low of $1.22 and a one year high of $5.12. The stock has a market capitalization of $15.91 million, a PE ratio of -0.33 and a beta of 0.83.

Synlogic (NASDAQ:SYBX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.17. Synlogic had a negative net margin of 2,284.65% and a negative return on equity of 207.84%. As a group, equities analysts forecast that Synlogic will post -2.71 EPS for the current year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.